某学术中心对遗传触发型主动脉及动脉瘤与夹层的检测模式
该回顾性队列研究描述了2010至2015年间某学术医学中心因临床怀疑遗传性血管病而转诊进行血管遗传检测的实践。在75例接受检测的患者中,36%发现致病突变;有家族史且已确诊突变者检出率最高(57.1%),其次为主动脉根部及升主动脉瘤或夹层患者(42.3%)。作者认为基于个人史或家族史的选择性检测收益合理,检测应在遗传咨询和结果解读的专业知识下进行。
要点
- 有家族史且已确诊突变者致病突变检出率最高,为57.1%。
- 主动脉根部及升主动脉瘤或夹层患者检出率为42.3%。
- 总体致病突变检出率为36%。
核心结论
- 在疑似遗传触发型血管病的患者中,基于个人史或家族史进行选择性遗传检测时,临床血管遗传检测的收益合理。
- 这些检测应在遗传咨询和遗传检测结果解读的适当专业知识下进行。
- 在阳性家族史背景下遗传检测阴性结果显示了检测的局限性和已知导致遗传触发型主动脉及动脉瘤与夹层的突变的局限性,并支持发现新基因的必要性。
研究设计与样本
- 回顾性队列研究,纳入2010年至2015年间在某学术医学中心因血管遗传检测转诊的患者。
- 通过当前操作术语诊断代码81405、81408和81479(包括马凡综合征、Loeys-Dietz综合征、动脉瘤-骨关节炎综合征、COL3A1及家族性胸主动脉瘤 panel)及胶原血管实验室数据库审查识别患者。
- 共96例患者(44.3%男性;中位年龄40.8岁)因疑似遗传性血管病转诊;75例被认为与主动脉或动脉瘤及夹层相关的遗传性突变而进行遗传检测。
主要发现
- 遗传检测最常见原因为个人史有主动脉或动脉瘤及夹层(62.3%;平均年龄45.8 ± 11.1岁),其次为无个人史的家族史(26.6%;年龄28.8 ± 17.9岁)。
- 最常见的遗传检测为家族性胸主动脉瘤基因 panel(44%),其次为血管型埃勒斯-当洛斯综合征单基因检测(33.3%)。
- 遗传检测在36%的病例中识别出致病突变。
- 识别致病突变的最高可能性见于有家族史且已确诊突变者(57.1%),其次为主动脉根部及升主动脉瘤或夹层患者(42.3%)。
临床怎么用
- 作者认为,在疑似遗传触发型血管病的患者中,基于个人史或家族史进行选择性临床血管遗传检测的收益合理。
- 作者认为,这些检测应在遗传咨询和遗传检测结果解读的适当专业知识下进行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The contemporary practice of testing for genetically triggered aortic and arterial aneurysms and dissections is not well described. This study aimed to describe this practice at a tertiary care academic center and to ascertain the yield of testing in establishing the diagnosis in patients referred on the basis of clinical suspicion. METHODS: This is a retrospective cohort study of patients referred for vascular genetic testing at an academic medical center between 2010 and 2015. Patients were identified by Current Procedural Terminology diagnostic codes 81405, 81408, and 81479 for genetic testing (Marfan syndrome, Loeys-Dietz syndrome, aneurysms-osteoarthritis syndrome, COL3A1, and familial thoracic aortic aneurysm panel [ACTA2, COL3A1, TGFBR1, TGFBR2, SMAD3, TGFB2, MYLK, MYH11, and PRKG1 genes]) and by review of the collagen vascular laboratory database for genetic testing results. Data abstracted included demographics, clinical history, reason for referral, family history, referring provider type, and outcomes of genetic testing. RESULTS: Ninety-six patients (44.3% male; median age, 40.8 years) were referred for suspected genetic vascular disease. Genetic testing was performed in 75 cases thought to have heritable mutations related to aortic or arterial aneurysms and dissections. The most common reason for genetic testing was a personal history of aortic or arterial aneurysms and dissections (62.3%; mean age, 45.8 ± 11.1 years), followed by a family history of aortic or arterial aneurysms and dissections without a personal history (26.6%; age, 28.8 ± 17.9 years). The most common genetic testing performed was a familial thoracic aortic aneurysm gene panel (44%), followed by single gene testing for vascular Ehlers-Danlos syndrome (33.3%). Genetic testing identified a pathogenic mutation in 36% of the cases. The highest likelihood of identifying a pathogenic mutation was in those who had a family history with an already diagnosed mutation (57.1%), followed by patients with aortic root and ascending aortic aneurysm or dissection (42.3%). CONCLUSIONS: In patients with suspected genetically triggered vascular disease, the yield of clinical vascular genetic testing is reasonable when selective genetic testing is performed on the basis of personal or family history. These tests should be obtained with appropriate expertise in genetic counseling and interpretation of genetic testing results. Negative genetic test results in the setting of a positive family history demonstrate the limits of testing and known mutations leading to genetically triggered aortic and arterial aneurysms and dissections and support the need for novel gene discovery.
引用
- Hicks KL, Byers PH, Quiroga E, et al. Testing patterns for genetically triggered aortic and arterial aneurysms and dissections at an academic center. J Vasc Surg. 2018. PMID: 29510914. doi:10.1016/j.jvs.2017.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。